Fundraising Fox
/Companies
Sign in

KromaTiD

Longmont, US · Founded 2022 · Delaware corporation · 1 known investors

Find your way into KromaTiD

Sign up to see every warm intro you have to KromaTiD

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the KromaTiD team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Kromatid provides single-cell structural genomic analysis tools for cell and gene therapy companies, enabling assessment of genomic integrity and identification of complex structural rearrangements during therapy development. The company serves biotech and medtech organizations working on gene editing and cell therapy from early research through clinical trials.

AI & Machine LearningBiotechDeep TechMedical Devices

Founders & leadership

AJ
Andrew JostExecutive
JC
James ChomasExecutive
CT
Christopher TompkinsExecutive
SB
Susan BaileyNamed on SEC filing
JB
Joel BedfordNamed on SEC filing

Board

TO
Terry OpgenorthBoard director
JB
Jack BallBoard director
PG
Priyadarshini GogoiBoard director
WY
Walter YoungBoard director
NS
Nick SaccomanoBoard director
GO
Ginny OrndorfBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$16M disclosed across 5 of 6 rounds · 2016–2025

▶$3.6MraisedJul 2025 · 57 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew JostExecutive Officer
  • Jack BallDirector
  • James ChomasExecutive Officer, Director
  • Priyadarshini GogoiDirector
  • Walter YoungDirector
  • Terry OpgenorthDirector
Offering amount
$5M
Amount sold
$3.6M
First sale
Jul 2025
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.1MraisedJan 2024 · 63 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • ANDREW JOSTExecutive Officer
  • JACK BALLDirector
  • TERRY OPGENORTHDirector
  • WALTER YOUNGDirector
  • JAMES CHOMASDirector
  • DAVID BRUNELDirector
  • PRIYADARSHINI GOGOIDirector
  • NATHAN WOODExecutive Officer, Director
Offering amount
$4.2M
Amount sold
$2.1M
First sale
Jan 2024
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.9MraisedOct 2021 · 61 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • David BrunelDirector
  • Walter YoungDirector
  • Priyadarshini GogoiDirector
  • Nathan WoodExecutive Officer, Director
  • James ChomasDirector
  • Vic MyerDirector
  • Terry OpgenorthDirector
Offering amount
$10M
Amount sold
$7.9M
First sale
Sep 2021
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.9MraisedAug 2019 · 4 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher TompkinsExecutive Officer, Director
  • Terry OpgenorthDirector
  • Joel BedfordDirector
  • Ginny OrndorfDirector
  • Nick SaccomanoDirector
  • Gordon LinkExecutive Officer
Offering amount
$2M
Amount sold
$1.9M
First sale
Feb 2019
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$622.7KraisedJan 2017 · 16 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Susan BaileyExecutive Officer
  • Nick SaccomanoDirector
  • Joel BedfordDirector
  • Ginny OrndorfDirector
  • Christopher TompkinsExecutive Officer, Director
  • Terry OpgenorthDirector
Offering amount
$1M
Amount sold
$622.7K
First sale
Dec 2016
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

BYJU'SBYJU'S offers online learning programs, video lessons, and a personalized learning app for students in India, including tutoring and exam-preparation programs for competitive tests such as JEE and NEET.

Companies working in the same space as KromaTiD.

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$1.7M
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$700.5K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$206.6K
NASAPhase II2010$600K
NASAPhase I2009$100K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

KromaTiD Receives $2.0 Million of Growth Capital Investment from BroadOak Capital Partnersprnewswire.com · Apr 2021

Frequently asked questions

What does KromaTiD do?
Kromatid provides single-cell structural genomic analysis tools for cell and gene therapy companies, enabling assessment of genomic integrity and identification of complex structural rearrangements during therapy development. The company serves biotech and medtech organizations working on gene editing and cell therapy from early research through clinical trials.
Who are KromaTiD's investors?
KromaTiD's investors include BroadOak Capital Partners.
How much funding has KromaTiD raised?
KromaTiD has disclosed $16M raised across 5 of its 6 known rounds.
Where is KromaTiD headquartered?
KromaTiD is headquartered in Longmont, US.